Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

European biosimilars hit AbbVie’s Humira revenues in Q4

Strong full year growth, but M&A speculation will linger

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links